COPD chronic obstructive pulmonary asthma

The defining structural element found in rolipram and its relatives is the dialkoxyphenyl (catechol) moiety. Although the development of rolipram (then for depression) was terminated early, many companies have since disclosed PDE4 inhibitors intended primarily for indications such as asthma and COPD (chronic obstructive pulmonary disease) [58], For a long time, cilomilast (Ariflo, 54) has appeared to be ahead in this race [59], In November 2003, GSK received an approvable letter from the FDA, despite the FDA advisory panel s earlier negative opinion of the compound. The extent to which new studies may have been requested by the FDA and will delay approval remains to be seen. 

A team at Hoffmann-La Roche, in 2013, reported the application of this reaction as a key step in an efficient large-scale synthesis (about 3 kg) of a naphthylacetic acid CRTH2 receptor (involved in inflammation events, and thus important therapeutically for the treatment of asthma, allergic inflammation, COPD (chronic obstructive pulmonary disease), allergic rhinitis, and atopic dermatitis) antagonist, which is a naphthylacetic acid (Scheme 1.57) [180]. This whole process was scaled up to produce over 2 kg of the active pharmaceutical ingredient (API). 

The symptoms of many chronic diseases, such as rheumatoid arthritis, multiple sclerosis, asthma and chronic obstructive pulmonary disease (COPD) are caused in large part by an excessive and chronic inflammatory response and are therefore potential human diseases for drugs which inhibit the SSAO/VAP-1 activity. Notably, it has been recently shown that patients suffering from either atopic eczema or psoriasis, both chronic inflammatory skin disorders, demonstrate an increase in SSAO/VAP-1 positive vessels in their skin compared to skin from healthy controls [47,48]. 

Aerosolised medicines have been used for centuries to treat respiratory diseases, with inhalation therapy for the airways focused primarily on the treatment of asthma and chronic obstructive pulmonary disease (COPD). The development of new products for delivery to the lungs for these respiratory diseases includes new steroids and beta agonists plus combination products featuring both agents. New classes of anti-asthma medication are also being developed for inhalation with the aim of delivering them directly to the inflamed airways. 

The first commercially available DPI system appeared on the market in 1949, developed and marketed by Abbott under the name Aerohaler. Like all early pulmonary drug-delivery devices, it delivered small-molecule compoimds (bronchodilators or inhaled corticosteroids) to the airways (not necessarily the deep limg) for the treatment of asthma or chronic obstructive pulmonary disease. Table 6 lists some of the early DPI systems used for asthma and COPD the energy somces in these devices were mechanical and patient inspiration. 

Many disorders benefit from exercise (Pederson Saltin, 2005). These include asthma, cancer, chronic heart failure, coronary artery disease, chronic obstructive pulmonary disease (COPD), depression, type 1 diabetes melUtus, type 2 diabetes melUtus, hypertension, intermittent claudication, osteoarthritis, osteoporosis, rheumatoid arthritis and obesity. 

Particulate matter air pollution is especially harmful to people with lung disease such as asthma and chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, as well as people with heart disease. Exposure to particulate air pollution can trigger asthma attacks and cause wheezing, coughing, and respiratory irritation in individuals with sensitive airways. It was estimated in one major study that the excess risk of total mortality is 6.2% per each increase in 10pgPM2.s/m and 9.3% for cardiopulmonary mortality. ... 

The benefits of the use of (3-blockade appear to exceed by far the risks of bronchospasm in patients diagnosed with chronic obstructive pulmonary disease (COED) and/or suppression of hypoglycemic responses in diabetics. COPD is very different from bronchospas-tic asthma. Young people with asthma have highly reactive airways and can die within hours of a bronchospasm in response to an exposure to an external agent. This highly reversible dynamic condition contrasts sharply with the destruction of connective tissue in lung parenchyma and dead airway sacs that are not very reactive. This is a very different phenomenon. 

PEE-IV Inhibitors Selective inhibitors of phosphodiesterase IV (PDE4) are in development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Two of them contain fluorine atoms roflumilast (preregistered) bears a difluoromethyl ether and AWD-12-281 (Phase II) has a single fluorine atom (Figure 8.51). 

Asthma, chronic obstructive pulmonary disease (COPD) Inhalation 12-mcg capsule ql2h. 

Unlabeled Uses Bronchial asthma, chronic obstructive pulmonary disease (COPD), cardiogenic shock, overt cardiac failure, second or third degree AV block, severe sinus bradycardia... 

Respiratory system (chronic obstructive pulmonary disease [COPD emphysema, chronic bronchitis], acute obstructive lung disease [asthma], chronic restrictive lung disease [connective tissue lung disease])... 

Albuterol Selective B2 agonist Prompt, efficacious bronchodilation Asthma, chronic obstructive pulmonary disease (COPD) drug of choice in acute asthmatic bronchospasm Aerosol inhalation duration several hours also available for nebulizer and parenteral use Toxicity. Tremor, tachycardia t overdose arrhythmias... 

Inhalation aerosols have been used for the delivery of drugs to the respiratory system since the mid-1950s. The most common dosage form for inhalation is the metered-dose inhaler (MDI), by which the drug is delivered from a pressurized container using a liquefied gas propellant. Medication delivered via this dosage form has allowed for a quick therapeutic response to the symptoms of asthma, emphysema, and chronic obstructive pulmonary disease (COPD), and has resulted in an improvement in the quality of life for millions of asthma sufferers. 

Smoking leads to respiratory problems other than lung cancer. It causes chronic bronchitis, emphysema, and lower resistance to flu and pneumonia. It worsens asthma symptoms in adults and children. As these problems persist, chronic obstructive pulmonary disease (COPD, airway obstruction) develops. Eighty to 85% of deaths due to COPD are from smoking. The role of nicotine in chronic lung diseases such as COPD, emphysema, and asthma is uncertain. However it is known that nicotine can cause an enzyme to be released which is able to destroy parts of the lungs as is seen in emphysema. 

Blockade of the 2 receptors in bronchial smooth muscle may lead to an increase in airway resistance, particularly in patients with asthma. Betai-receptor antagonists such as metoprolol or atenolol may have some advantage over nonselective antagonists when blockade of Bi receptors in the heart is desired and -receptor blockade is undesirable. However, no currently available i-selective antagonist is sufficiently specific to completely avoid interactions with 62 adrenoceptors. Consequently, these drugs should generally be avoided in patients with asthma. On the other hand, some patients with chronic obstructive pulmonary disease (COPD) may tolerate these drugs quite well. 

The pharmacists of Care-Rite Pharmacy also developed patient educational tools to be used during the patient assessment and patient education components of the Pharmacy Check-up Service. Because many of the targeted patients have similar medical conditions, education materials were developed for specific disease states, including hypertension, ischemic heart disease, diabetes, asthma, chronic obstructive pulmonary disease (COPD), etc. Also, educational materials were developed for certain therapeutic classes of medications. The Care-Rite pharmacists also determined that many patients needed individualized education materials, so they implemented a drug information/educational service as part of the MTM service. With this service, patients can ask questions regarding their medical conditions and/or drug therapies. The pharmacists will research and provide an individualized written response for each patient. 

---